Status: Not yet recruiting
A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants
This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity, with or without weight-related health conditions. Participants in this study will receive subcutaneous (under the skin) injections of either TE-8105 or placebo for 25 weeks. The total study duration, including screening and follow-up visits, is approximately 8 months.
Participants needed: 204
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Immunwork, Inc.Updated: Oct 5, 2026Locations: 2
Eligibility criteria
Able to understand the full nature, purpose, and risks of the study and provide... [+5]
An abnormal clinical laboratory test value specified in the protocol. [+31]